Visit of the Head of the Food and Drug Organization to Pars Isotope Company

The Head of the Food and Drug Organization visited the cyclotron radiopharmaceutical production center, the Secondary Standard Dosimetry Laboratory (SSDL), and the ongoing construction projects of Pars Isotope Company, and was briefed on the latest status of the complex’s production and development activities.

During this visit, Dr. Pirsalehi, referring to the wide range of activities of Pars Isotope, stated: “The production of over 70 types of radiopharmaceuticals in this company plays a significant role in the country’s healthcare system and supplies a major portion of the needs of diagnostic and therapeutic centers.”

He emphasized the importance of developing domestic capacities, adding: “Some radiopharmaceuticals have a very short half-life, making their import practically impossible. Therefore, expanding domestic production centers is an undeniable necessity, and patients’ rapid access to medication depends on these centers.”

The Head of the Food and Drug Organization continued, referring to the Ministry of Health’s plan to increase the number of PET diagnostic centers from 25 to 50, stating: “To meet the needs of these centers, establishing production units in five provinces of the country is essential so that the supply of pharmaceuticals for neighboring provinces can also be carried out more rapidly.”

He emphasized the crucial role of radiopharmaceuticals in treating serious diseases, adding: “By enabling precise and targeted imaging, these pharmaceuticals directly contribute to saving patients’ lives. The Food and Drug Organization also monitors the strict adherence to GMP standards in the production process of these products.”

In conclusion, Dr. Pirsalehi, while expressing satisfaction with the production conditions at Pars Isotope Company, emphasized the continuation of close cooperation for the introduction of new products to the country’s pharmaceutical list and expressed hope that in the near future, we will witness the production and supply of a new generation of advanced radiopharmaceuticals in the country.